KALA News and Press, Kala Pharmaceuticals Inc. From 08/22/19

The U.S. is by far the global leader in healthcare research, and the reason is that the government promotes the research and development of innovative drugs and devices through reimbursements to the physicians who purchase them. It's this very important drug payback system that confers a huge ad...

Insider support and upcoming catalysts. A pharmaceutical company's bull thesis usually is strengthened by both of these, and Kala Pharmaceuticals, Inc. ( KALA ) has no shortage of either one. But as the date of the FDA review for Kala's New Drug Application on KPI-121 0.25% neared, the stock...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , iTunes...

Kala Pharmaceuticals (NASDAQ: KALA ) may encounter some volatility after receiving a CRL from the FDA regarding its marketing application for dry eye disease candidate KPI-121. The agency stated that another clinical will be needed. More news on: Kala Pharmaceuticals, Inc., Healthcare st...

-- Targeting Topline Data from STRIDE 3 by the End of 2019 -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that it received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Company’s new drug application (NDA) for KPI...

Kala Pharmaceuticals, Inc. (KALA) Q2 2019 Earnings Conference Call August 6, 2019, 8:00 am ET Company Participants Mary Reumuth - CFO Mark Iwicki - Chairman, President & CEO Kim Brazzell - CMO Todd Bazemore - COO Conference Call Participants Biren Amin - Jefferies E...

–Conference Call and Webcast Today at 8:00 a.m. ET– Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug D...

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that it will report second quarter 2019 fina...

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that it will present at the Jefferies 2019 ...